SCHEMBL508979

SCHEMBL508979

C1CCC(CN2CCNCC2)CC1

nearest known ligand 0.67

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CHRM5 P08912 3/20 0.67
ADRA2C P18825 1/20 0.67
ACHE P22303 1/20 0.57
RAD52 P43351 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.46
SIGMAR1 Q99720 2/20 0.44
CHRM3 P20309 1/20 0.44
OPRM1 P35372 4/20 0.44
OPRL1 P41146 4/20 0.44
OPRK1 P41145 2/20 0.44
OPRD1 P41143 1/20 0.44
CHRM2 P08172 1/20 0.43
CHRM4 P08173 1/20 0.43
CHRM1 P11229 1/20 0.43
CASP1 P29466 1/20 0.40
CASP4 P49662 1/20 0.40
CASP5 P51878 1/20 0.40
GBA1 P04062 1/20 0.39
TRPC5 Q9UL62 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11261525 1.00 CHRM5 (0.67) CHRM5ADRA2CACHERAD52SMN1; SMN2
Hydrochloric Acid SCHEMBL4711077 0.98 CHRM5 (0.64) CHRM5ADRA2CACHERAD52SMN1; SMN2
Piperazine SCHEMBL1306030 0.98 CHRM5 (0.64) CHRM5ADRA2CACHERAD52SMN1; SMN2
Hydrochloric Acid SCHEMBL8187324 0.98 CHRM5 (0.64) CHRM5ADRA2CACHERAD52SMN1; SMN2
SCHEMBL1846759 0.98 CHRM5 (0.62) CHRM5ADRA2CACHERAD52SMN1; SMN2
Hydrochloric Acid SCHEMBL1307635 0.95 CHRM5 (0.60) CHRM5ADRA2CACHERAD52SMN1; SMN2
SCHEMBL18091085 0.94 CHRM5 (0.65) CHRM5ADRA2CACHERAD52SMN1; SMN2
SCHEMBL211956 0.93 CHRM5 (0.56) CHRM5ADRA2CACHERAD52SMN1; SMN2
Hydrochloric Acid SCHEMBL2130817 0.91 CHRM5 (0.54) CHRM5ADRA2CACHERAD52SMN1; SMN2
SCHEMBL92626 0.88 CHRM5 (0.48) CHRM5ADRA2CACHERAD52SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 260 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118684644-A Eupatilin derivative containing piperazine structure and preparation method and application thereof 南阳医学高等专科学校 2024-09-24 CN claimed
US-11787785-B2 Pyrazolopyridine derivatives and uses thereof NOVARTIS AG (CH) 2023-10-17 US claimed
US-20230108325-A1 Pyrazolopyridine Derivatives and Uses thereof NOVARTIS AG (CH) 2023-04-06 US claimed
CN-104046246-B The chemical-mechanical planarization of tungsten-containing substrate 气体产品与化学公司 2016-06-15 CN claimed
US-20140273458-A1 Chemical Mechanical Planarization for Tungsten-Containing Substrates AIR PRODUCTS AND CHEMICALS, INC. (US) 2014-09-18 US claimed
EP-2779217-A2 Chemical mechanical planarization for tungsten-containing substrates AIR PRODUCTS AND CHEMICALS, INC. (US) 2014-09-17 EP claimed
CN-104046246-A Chemical Mechanical Planarization for Tungsten-Containing Substrates AIR PROD & CHEM 2014-09-17 CN claimed
CN-1025999-C Imidazo [4,5-B] quinolinyloxyalkanoic acid amides with enhanced water solubility BRISTOL MYERS SQUIBB CO (US) 1994-09-28 CN claimed
CN-1051359-A Improved imidazo [4, the 5-b] quinolinyloxyalkanoic acid amides of water-soluble degree BRISTOL MYERS SQUIBB CO (US) 1991-05-15 CN claimed
EP-3796900-B1 TRITERPENE AMINE DERIVATIVES DFH THERAPEUTICS (US) 2026-04-08 EP disclosed
US-12440484-B2 1,3,4-oxadiazole homophthalimide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same CHONG KUN DANG PHARMACEUTICAL CORPORATION (KR) 2025-10-14 US disclosed
WO-2025054238-A1 MULTI-TARGET DIRECTED LIGANDS FOR ALZHEIMER'S DISEASE THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2025-03-13 WO disclosed
CN-118684644-A Eupatilin derivative containing piperazine structure and preparation method and application thereof 南阳医学高等专科学校 2024-09-24 CN disclosed
CN-113874369-B 1,3, 4-Oxadiazole homophthalimide derivative compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions containing the same 株式会社 钟根堂 2024-08-27 CN disclosed
US-4353826-A ANTITUBERCULAR ANTIBIOTICS CIBA-GEIGY CORPORATION (US) 1982-10-12 US disclosed
US-4301129-A BY TREATING AN INORGANIC CYANIDE WITH A BORON TRIFLUORIDE DONOR THIOKOL CORPORATION (US) 1981-11-17 US disclosed
US-4261891-A BACTERICIDES, ANTITUBERCULAR AGENTS CIBA-GEIGY CORPORATION (US) 1981-04-14 US disclosed
EP-0009382-A1 Production of cyanoborohydrides THIOKOL CORPORATION (US) 1980-04-02 EP disclosed
US-4115569-A PARASITICIDES HOECHST AKTIENGESELLSCHAFT (DE) 1978-09-19 US disclosed
US-4005077-A DERIVATIVES OF RIFAMYCIN S OR SV CIBA-GEIGY CORPORATION (US) 1977-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11787785-B2 Pyrazolopyridine derivatives and uses thereof HBZ, ZFX, WIZ CHRM5 4105/4885ADRA2C 2057/4885ACHE 4474/4885
US-12440484-B2 1,3,4-oxadiazole homophthalimide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same HDAC1, HDAC11, HDAC3 CHRM5 4103/4885ADRA2C 4518/4885ACHE 719/4885
US-20230108325-A1 Pyrazolopyridine Derivatives and Uses thereof HBZ, ZFX, WIZ CHRM5 4105/4885ADRA2C 2057/4885ACHE 4474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.